Profile data is unavailable for this security.
About the company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
- Revenue in USD (TTM)18.69m
- Net income in USD-6.72m
- Incorporated2000
- Employees100.00
- LocationMediwound Ltd42 Hayarkon StreetYAVNE 8122745IsraelISR
- Phone+972 89324010
- Fax+972 89324011
- Websitehttps://www.mediwound.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
aTyr Pharma Inc | 353.00k | -50.39m | 135.50m | 56.00 | -- | 1.40 | -- | 383.85 | -0.9537 | -0.9537 | 0.0066 | 1.43 | 0.0033 | -- | 0.0497 | 6,303.57 | -46.57 | -45.45 | -54.04 | -52.74 | -- | -- | -14,276.77 | -784.19 | -- | -- | 0.0208 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 138.39m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Relmada Therapeutics Inc | 0.00 | -98.79m | 138.50m | 20.00 | -- | 1.62 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Coya Therapeutics Inc | 6.00m | -7.99m | 140.34m | 8.00 | -- | 3.90 | -- | 23.38 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
Beyondspring Inc | 1.55m | -27.51m | 141.29m | 67.00 | -- | -- | -- | 91.16 | -0.7043 | -0.7043 | 0.0397 | -0.4637 | 0.0321 | -- | -- | 21,232.88 | -60.79 | -91.82 | -81.96 | -118.82 | -- | -- | -1,895.29 | -9,233.73 | -- | -- | -- | -- | 0.00 | -- | 48.15 | -- | -14.86 | -- |
Mediwound Ltd | 18.69m | -6.72m | 143.32m | 100.00 | -- | 4.41 | -- | 7.67 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Acrivon Therapeutics Inc | 0.00 | -50.07m | 143.49m | 56.00 | -- | 1.03 | -- | -- | -2.28 | -2.28 | 0.00 | 6.25 | 0.00 | -- | -- | 0.00 | -41.93 | -- | -44.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -91.88 | -- | -- | -- |
Nuvectis Pharma Inc | 0.00 | -22.26m | 148.19m | 13.00 | -- | 11.91 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Armata Pharmaceuticals Inc | 4.53m | -69.05m | 148.21m | 66.00 | -- | -- | -- | 32.72 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
CytomX Therapeutics Inc | 101.21m | -569.00k | 148.31m | 120.00 | -- | -- | 92.35 | 1.47 | -0.0191 | -0.0191 | 1.37 | -0.7049 | 0.4375 | -- | 5.14 | 843,450.00 | -0.246 | -21.53 | -0.7382 | -32.32 | -- | -- | -0.5622 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Galectin Therapeutics Inc | 0.00 | -45.44m | 149.06m | 12.00 | -- | -- | -- | -- | -0.763 | -0.763 | 0.00 | -0.8225 | 0.00 | -- | -- | 0.00 | -208.11 | -84.71 | -417.72 | -104.98 | -- | -- | -- | -- | -- | -15.30 | 5.96 | -- | -- | -- | -26.63 | -- | -- | -- |
Syros Pharmaceuticals Inc | 8.80m | -104.96m | 149.85m | 117.00 | 3.84 | 3.33 | -- | 17.04 | 1.52 | 1.52 | 0.365 | 1.75 | 0.0407 | -- | 5.12 | 75,170.94 | -48.54 | -49.48 | -57.40 | -58.43 | -- | -- | -1,193.45 | -700.90 | -- | -- | 0.5309 | -- | -36.65 | 68.33 | -9.35 | -- | 8.61 | -- |
Telomir Pharmaceuticals Inc | 0.00 | -4.23m | 150.57m | 2.00 | -- | 69.13 | -- | -- | -0.1429 | -0.1429 | 0.00 | 0.0736 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | 0.3805 | -- | -- | -- | -518.37 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -117.86m | 150.65m | 168.00 | -- | 0.9955 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
I-Mab ADR | 3.83m | -202.81m | 150.91m | 318.00 | -- | 0.6348 | -- | 39.45 | -2.29 | -2.29 | 0.0445 | 2.95 | 0.0083 | -- | -- | -- | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Point72 Asset Management LPas of 31 Dec 2023 | 821.50k | 8.92% |
Rosalind Advisors, Inc.as of 31 Dec 2023 | 606.75k | 6.59% |
DAFNA Capital Management LLCas of 31 Dec 2023 | 257.65k | 2.80% |
Uniplan Investment Counsel, Inc.as of 31 Dec 2023 | 145.27k | 1.58% |
Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 132.10k | 1.44% |
Yelin Lapidot Mutual Fund Management Ltd.as of 31 Dec 2023 | 125.49k | 1.36% |
Sargent Investment Group LLCas of 31 Dec 2023 | 109.19k | 1.19% |
Silverberg Bernstein Capital Management LLCas of 31 Dec 2023 | 78.98k | 0.86% |
Renaissance Technologies LLCas of 31 Dec 2023 | 55.94k | 0.61% |
Sphera Funds Management Ltd.as of 31 Dec 2023 | 48.98k | 0.53% |